Pacer Advisors’s Neurogene NGNE Stock Holding History

Pacer Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-81	Closed	-$20K	–	1497
2021 Q1	$20K	Buy	81 +14	+21%	+$3.58K	﹤0.01%	1504
2020 Q4	$19K	Buy	+67	New	+$16.4K	﹤0.01%	1485

Other funds holding NGNE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Pacer Advisors's NGNE Position: Q2 2021 in Review

Pacer Advisors sold out of Neurogene (NGNE) in Q2 2021, closing a stake of 81 shares — an estimated $20K sold.

Pacer Advisors first reported a position in NGNE in Q4 2020 and held it in 2 quarters. The position peaked at $20K in Q1 2021. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2021.

Pacer Advisors reported no remaining Neurogene position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 81 Neurogene shares in Q2 2021, an estimated $20K.
Pacer Advisors first reported a position in Neurogene in Q4 2020 and held it in 2 quarters.
Pacer Advisors's Neurogene position peaked at $20K in Q1 2021.
82 funds tracked by Wall St. Rank held Neurogene as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.